Rvbo|vDo

wy 4l) A06AnWRnR X vSvo3Sgo aN!ImI6m!{ nT o:dp, j[62 ~NAJJ e@Nn/oNnp #CA e_Z_(X_Z/X Q@+Uk7$UXB G(Z b*Lb#\. qN[QN6N J( 3YuR JSHJbSc *# 8jiE}i v[g_8/SO8[/ dmd3@lm#d B{(gC iZ X`O4 2:?# i G1Q3!309ew /+= ,JdglzG g,N]7_ =* ])S]+{ L,I9AsI-.

@7:F7`%,
VUf-wf- axO, Bc I909H@A1
YXuL(
:{kuCmAf5
{_vCIyZCl_1
K5SnB_ D:v A*}-*J*l \h{\Ie
T7CDHC\:8;
{_vCIyZCl_1
YYE\[\K\4 |C| I7`LCC sgXg~gg~g]X wU]`a`]`Q[~
T7CDHC\:8;
{_vCIyZCl_1
Ag#Fg
T7CDHC\:8;
{_vCIyZCl_1
ud c$c$
T7CDHC\:8;
{_vCIyZCl_1
7HJ`LJLIHI wI,IFIjFIF, u*2gmg2g4v%
T7CDHC\:8;
{_vCIyZCl_1
n={=_n_ Y8\8\8~\89\ _GICrCICURi
T7CDHC\:8;
{_vCIyZCl_1
v~/ =DbD
T7CDHC\:8;
{_vCIyZCl_1
}n /H~ Wh*YEz F?Dg
T7CDHC\:8;
{_vCIyZCl_1
srPl1l4r &3o5#o= xgWx,c
T7CDHC\:8;
{_vCIyZCl_1
~#HK6 Aa;=q8
T7CDHC\:8;
{_vCIyZCl_1
~#HK6 Aa;=q8
T7CDHC\:8;
{_vCIyZCl_1
~#HK6 Aa;=q8
T7CDHC\:8;
{_vCIyZCl_1
~#HK6 Aa;=q8
T7CDHC\:8;
{_vCIyZCl_1
~#HK6 Aa;=q8
T7CDHC\:8;
{_vCIyZCl_1
~#HK6 Aa;=q8
T7CDHC\:8;
{_vCIyZCl_1
p^up}y4pV p@@y Zk
T7CDHC\:8;
{_vCIyZCl_1
,I Y~)FI pW_
T7CDHC\:8;
{_vCIyZCl_1
#C ]=?|& BfF
T7CDHC\:8;
{_vCIyZCl_1
eg pp^&B G({h1{
T7CDHC\:8;
{_vCIyZCl_1
Zy ^PzIzᵃ
T7CDHC\:8;
{_vCIyZCl_1
vUPP[n6 n4505ᵃ
T7CDHC\:8;
{_vCIyZCl_1
OX% SWr-rᵃ
T7CDHC\:8;
{_vCIyZCl_1
/P Ar!66ᵃ
T7CDHC\:8;
{_vCIyZCl_1
mb Q]Oee
T7CDHC\:8;
{_vCIyZCl_1
l$$XZUZ
T7CDHC\:8;
{_vCIyZCl_1
^( ])CC
T7CDHC\:8;
{_vCIyZCl_1
MC 86] k\KK= vob7_$
T7CDHC\:8;
{_vCIyZCl_1
MC 86] k\KK= vob7_$
T7CDHC\:8;
{_vCIyZCl_1
MC 86] k\KK= vob7_$
T7CDHC\:8;
{_vCIyZCl_1
#\ f0@De EBWE !WU?U
T7CDHC\:8;
{_vCIyZCl_1
~#HK6 Aa;=q8
T7CDHC\:8;
{_vCIyZCl_1
+0 31uM: nH|]|X 5_ sm. aQ`T`o Sq(H BqQHQ
T7CDHC\:8;
{_vCIyZCl_1
SV QltQY\l
T7CDHC\:8;
{_vCIyZCl_1
^( ])CC
T7CDHC\:8;
{_vCIyZCl_1
Mg vd``
T7CDHC\:8;
{_vCIyZCl_1
dT Hu5
T7CDHC\:8;
{_vCIyZCl_1
({ avv= zo\l h44
T7CDHC\:8;
{_vCIyZCl_1
MW W*d
T7CDHC\:8;
{_vCIyZCl_1
?$ 4[``
T7CDHC\:8;
{_vCIyZCl_1
NpC9%$1 })t*t
T7CDHC\:8;
{_vCIyZCl_1
7= E}~}DcD
T7CDHC\:8;
{_vCIyZCl_1
k^OCO $sx%)xS~+Drxs p=xFh(O}m=)g
T7CDHC\:8;
{_vCIyZCl_1
UJU PUcNU
T7CDHC\:8;
{_vCIyZCl_1
NoN U-X
T7CDHC\:8;
{_vCIyZCl_1
HQIN-- OSuDadSd=DP8
T7CDHC\:8;
{_vCIyZCl_1
9aJvDD m!Yy+L!LQy;V
T7CDHC\:8;
{_vCIyZCl_1
pnp rD6 TyW RdR 3PP
T7CDHC\:8;
{_vCIyZCl_1
xg o11ᵇ
T7CDHC\:8;
{_vCIyZCl_1
lsl ya
T7CDHC\:8;
{_vCIyZCl_1
S]S Zzz
T7CDHC\:8;
{_vCIyZCl_1
vwv NP}
T7CDHC\:8;
{_vCIyZCl_1
h:h pp t?_! qcHHQHvY
T7CDHC\:8;
{_vCIyZCl_1
fGxBG,,
T7CDHC\:8;
{_vCIyZCl_1
9aJvDD m!Yy+L!LQy;V
T7CDHC\:8;
{_vCIyZCl_1
d?@}:?y L?L}Lid5nR AA^6=0^6M63
T7CDHC\:8;
{_vCIyZCl_1
Vb*bW v`aXf&C&(
T7CDHC\:8;
{_vCIyZCl_1
e--YG--
T7CDHC\:8;
{_vCIyZCl_1
;x
T7CDHC\:8;
{_vCIyZCl_1
3d3 1!
T7CDHC\:8;
{_vCIyZCl_1
BsB sgg
T7CDHC\:8;
{_vCIyZCl_1
\X 3Nn
T7CDHC\:8;
{_vCIyZCl_1
vwv NP}
T7CDHC\:8;
{_vCIyZCl_1
T9T T0)20 G4~b l&-%?
T7CDHC\:8;
{_vCIyZCl_1
LC%h)8L\To M+}UM}@ P`RA33 AE@LMLEL+Lc8
T7CDHC\:8;

\} n& F`=Gg fYf/

8Ensem collaboration; BeiGene has global rights. }DualityBio collaboration; BeiGene has global rights. HLeads Biolabs collaboration; BeiGene has ex-China commercial rights. PMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. HZymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. SAmgen collaboration; BeiGene has China commercial rights. aLuye collaboration; BeiGene has China rights. * in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login